- Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
- Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
- Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
- Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
- Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
- Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
More ▼
Key statistics
As of last trade, Moleculin Biotech Inc (MBRX:NAQ) traded at 4.99, 16.59% above the 52 week low of 4.28 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.02 |
---|---|
High | 5.04 |
Low | 4.85 |
Bid | 4.86 |
Offer | 5.12 |
Previous close | 5.15 |
Average volume | 15.30k |
---|---|
Shares outstanding | 2.31m |
Free float | 2.21m |
P/E (TTM) | -- |
Market cap | 11.90m USD |
EPS (TTM) | -12.94 USD |
Data delayed at least 15 minutes, as of May 24 2024 19:33 BST.
More ▼